Chai Discovery announces $130M Series B funding
Led by General Catalyst and Oak HC/FT, with Thrive Capital, OpenAI, and others participating. Annie Lamont and Hemant Taneja join the board. Funds support research and team growth.
See the latest news and media coverage for Chai Discovery. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI company designing drug-like antibodies
chaidiscovery.comLast updated
In short: Chai Discovery secured $130 million in Series B funding, reaching a $1.3 billion valuation and entering licensing deals with Pfizer and Eli Lilly.
Led by General Catalyst and Oak HC/FT, with Thrive Capital, OpenAI, and others participating. Annie Lamont and Hemant Taneja join the board. Funds support research and team growth.
Chai-2 designs full-length mAbs with high developability, atomic precision via Cryo-EM, and success against hard targets like GPCRs and peptide-MHC.
The company raised $100M and launched Chai-2 AI model for antibody design with double-digit success rates.
Chai-2 achieves 20% lab-validated hit rate across 50 targets, over 200× industry benchmarks. Discusses data-to-design process, rapid hypothesis testing, and enabling factors.
Pfizer (NYSE:PFE) has entered a new licensing agreement with Chai Discovery to use artificial...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive...
Emirates 24/7 — Chai Discovery, a biotechnology startup backed by OpenAI, has secured a massive $130 million Series B funding round, raising its valuation to...
Track Chai Discovery and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Chai Discovery and other trending companies.